Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XBiotechSTU:4XB 38 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:4XB with a GF Score™ of 38/100 and a GF Value™ of €0.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, XBiotech ranks worse than 106496.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. XBiotech's EBITDA for the
three
months ended in Mar. 2026 was €-4.43 Mil. XBiotech's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, XBiotech's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
XBiotech (STU:4XB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
XBiotech EBITDA Margin % Related Terms
XBiotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for XBiotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4XB vs ACRV, EXOZ, BYSI: EBITDA Margin % Comparison
For the Biotechnology subindustry, XBiotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XBiotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XBiotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where XBiotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBiotech (STU:4XB) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on XBiotech and its competitors. According to the industry distribution chart, XBiotech ranks #999999 out of 939 companies in the Biotechnology industry.
Is XBiotech's EBITDA Margin % too high?
XBiotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, XBiotech ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XBiotech has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XBiotech's EBITDA Margin % compare to ACRV and EXOZ?
According to the Biotechnology industry distribution chart, XBiotech ranks #999999 out of 939 companies for EBITDA Margin %. This places XBiotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on XBiotech and its competitors. XBiotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
Based on GuruFocus' analysis, XBiotech (STU:4XB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €2.00 — trading 1233.3% above its estimated fair value. The current EBITDA Margin % is 0.00%. XBiotech's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For XBiotech (STU:4XB), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XBiotech (STU:4XB) Overvalued in 2026?
Based on GuruFocus' analysis, XBiotech stock appears to be overvalued.
The current stock price of €2.00 is trading 1233.3% above its estimated GF Value™ of €0.15.
GuruFocus considers XBiotech to be Significantly Overvalued.
Key valuation signals for STU:4XB:
EBITDA Margin %: 0.00%
GF Value™: €0.15 vs. price of €2.00 (1233.3% above fair value)
No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score
Get the complete analysis for STU:4XB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4XB has been successfully added to your 
